Oncology

Therapeutics, diagnostics and evidence shaping cancer care.

Lung Cancer Immunotherapy Needs Biomarkers Beyond PD-L1

This editorial reviews emerging biomarkers for immune checkpoint inhibitors in lung cancer, from blood-based indices to microbiome signals and integrated models.

By Dr. Revathy Mohan V.R., MBBS · Nov 1, 2026 · 6 min read

Oncology·Front Immunol

Nanomedicine and Innate Immunity Reshape Cancer Immunotherapy Strategies

A Frontiers in Immunology review examines how nanoparticles activate innate immunity, alter immune cells, and may improve cancer…

Nov 1, 2026

Oncology·Front Immunol

Osteosarcoma spatial ligand-receptor circuits explain immune resistance

A Frontiers in Immunology mini-review maps spatial ligand-receptor circuits in osteosarcoma, linking bone and lung niches to immune…

Nov 1, 2026

Oncology·Brain

Oligometastatic Breast Cancer Study Examines Prognosis and Progression Patterns

A study of hormone receptor–positive, HER2-negative oligometastatic breast cancer examines prognostic stratification and how progression unfolds over time.

Nov 1, 2026

Oncology·Cancer Disc

AACR white paper charts roadmap for cancer prevention science

AACR white paper outlines five priorities for cancer prevention, from precancer atlases and interception to obesity, disparities, and…

Nov 1, 2026

Oncology·Cancer Disc

Drug-Wide Association Study Examines Prescription Drugs and Digestive Cancer Risk

AACR case-control drug-wide association study explores hypothesis-generating links between prescription drugs and digestive cancer risk.

Nov 1, 2026

Oncology·Cancer Disc

VIOLETTE Phase II Tests Ceralasertib Plus Olaparib in Triple-Negative Breast Cancer

Phase II VIOLETTE study evaluated ceralasertib plus olaparib in advanced triple-negative breast cancer across three molecular strata.

Nov 1, 2026

Oncology·JCO

TNBC inflammatory biomarkers in Senegal show strong diagnostic signal

A Senegalese cohort found TNBC carried a distinct inflammatory blood profile, with NLR, CRP, and neutrophils offering discriminatory…

Nov 1, 2026

Oncology·JCO

HER2 and miR-21 detection in breast cancer moves toward digital assays

A review of 305 studies maps HER2 and miR-21 detection in breast cancer, comparing standard assays with digital…

Nov 1, 2026

Oncology·Br J Cancer

Type I IFN drives ILC plasticity in radiation-induced lung injury

Preclinical lung irradiation shifted ILC2 cells toward inflammatory ILC1 states, implicating type I interferon signaling in radiation lung…

Nov 1, 2026

Oncology

Therapeutics, diagnostics and evidence shaping cancer care.

In Brief The 5-minute rounds

New hypertension guideline lowers the treatment threshold to 130/80 mm Hg.
Phase 3 GLP-1 trial reports a 20% cut in major adverse cardiac events.
FDA clears a next-generation CAR-T therapy for relapsed lymphoma.
Meta-analysis links early mobilisation to shorter ICU length of stay.
Rapid guidance broadens empiric antibiotics for suspected sepsis.